Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...4748495051525354555657...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    [VIRTUAL] CDK4/6i adjustment & tumour response in the COVID-19 era () -  Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_262;    
    If receiving Denosumab, this was stopped in 72.4% (n= 92)... A short interruption of CDK4/6i and continuation of endocrine treatment alone, does not appear to adversely affect tumour response from this data. Continued monitoring of this approach during subsequent pandemic waves is required together with specific outcomes of SARS-CoV-2 in the metastatic breast cancer population to ensure evidence based decision making.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Clinical, Journal:  High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. (Pubmed Central) -  Mar 4, 2021   
    The pathophysiologic mechanisms of GIOP that lead to the detrimental effects on bone are not yet fully elucidated. Although GCs in an early and transitory period promote osteoclastic activity, in the current paper, we outline why GIOP is in fact a disease of the bone formation and then provide the rationale for the use of bone-forming agents as first-line therapy for patients with high fracture risk in GIOP.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    [VIRTUAL] Hypercalcemia of immobilization: an often-overlooked disorder () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_609;    
    Markers of bone resorption like serum and urine NTX are elevated and bone specific alkaline phosphatase is low to normal. Increasing mobility reverses hypercalcemia and Bisphosphonates and Denosumab are the approved medications to inhibit osteoclast mediated bone resorption.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial initiation date:  Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients (clinicaltrials.gov) -  Mar 1, 2021   
    P=N/A,  N=73, Completed, 
    Additional studies are needed to determine the degree of drug removal by TPE to allow for better guidance of administering these agents around TPE. Initiation date: May 2019 --> Jan 2020
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Clinical, Journal:  Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency. (Pubmed Central) -  Feb 26, 2021   
    The patient required intensive care monitoring for replacement of electrolytes. This case report emphasises the importance of screening and ongoing monitoring of risk factors for iatrogenic hypocalcaemia with denosumab treatment.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Review, Journal, Checkpoint inhibition:  The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL. (Pubmed Central) -  Feb 26, 2021   
    Additionally, the RANKL/RANK axis is a significant mediator of progesterone-driven mammary epithelial cell proliferation, potentially contributing to breast cancer initiation and progression...Clinical and experimental trials have emerged evaluating RANKL inhibition as an enhancer of the immune response, rendering resistant tumors responsive to immune therapies. Trials evaluating the combinatorial effect of immune checkpoint inhibitors and anti-RANKL treatment in double-positive (RANK+/ERBB2+) patients are encouraging.
  • ||||||||||  Prolia (denosumab) / Amgen, Kineret (anakinra) / SOBI
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) -  Feb 25, 2021   
    P1,  N=57, Completed, 
    Trials evaluating the combinatorial effect of immune checkpoint inhibitors and anti-RANKL treatment in double-positive (RANK+/ERBB2+) patients are encouraging. Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Feb 2021 | Trial primary completion date: Jun 2020 --> Feb 2021
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    [VIRTUAL] A RARE CASE OF REFRACTORY HYPOCALCAEMIA SECONDARY TO OSTEOBLASTIC BONE METASTASES FROM BLADDER CANCER. () -  Feb 24, 2021 - Abstract #ICE2021ICE_335;    
    We report a case of refractory hypocalcemia in a patient with metastatic bladder cancer with extensive osteoblastic bone metastases and history of denosumab administration...To our knowledge, no cases of hypocalcemia in bladder cancer with osteoblastic bone metastases have been reported. The possibility of osteoblastic metastasis should be considered in the differential of protracted and severe hypocalcemia.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Clinical, Journal:  Denosumab Use as a Predictor Variable for External Cervical Resorption: A Case-Control Study. (Pubmed Central) -  Feb 24, 2021   
    This should be done in order to improve our understanding of human physiology and pathology, as well as to improve anti-resorptive treatment and reduce side effects. Based on the binary logistic regression model, denosumab use could significantly predict the risk of developing ECR.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Journal:  Repurposing denosumab for recalcitrant bone healing. (Pubmed Central) -  Feb 23, 2021   
    All the three cases have shown complete bone union at a mean follow-up of 6.7 months (5-9 months) as assessed clinically and radiologically, and have observed no adverse effect of the therapy. Denosumab given in this dose aids fracture healing by increasing callus volume, density and bridges the fracture gap in recalcitrant fracture healing cases where the callus fails to consolidate.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    [VIRTUAL] Treatment of Osteoporosis Related to Adult Hypophosphatasia () -  Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_183;    
    Discussion In patients with HPP-related osteoporosis, case reports have described increased bone formation and decreased bone pain with anabolic treatment modalities (teriparatide or romosozumab)...In our case, we have used denosumab following a course of teriparatide. Ongoing research and monitoring is required to assess long-term safety and efficacy.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Journal:  Challenges in preventing bone loss induced by aromatase inhibitors. (Pubmed Central) -  Feb 20, 2021   
    Treatment approaches to prevent aromatase inhibitor-induced bone loss typically consist of an antiresorptive approach with bisphosphonates or the RANKL antibody denosumab...The choice of antiresorptive regime is further complicated by comorbidities and potential disease modifying effects of individual agents. This review summarizes the evidence of how aromatase inhibitors affect bone health and provides an update of clinical approaches to preserve bone strength in affected women.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Journal:  The effect of denosumab administration on bone metabolism for treatment of spinal metastasis. (Pubmed Central) -  Feb 20, 2021   
    At 6 months after denosumab intervention, measured TRAP-5b values were significantly lower compared to pre-intervention values in both the osteosclerotic lesion and osteolytic lesion groups. This change in bone metabolism marker values over time is one of the methods for evaluating the effect of treatment on bone tissue in cases of spinal metastasis.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Review, Journal:  Persistence and adherence to parenteral osteoporosis therapies: a systematic review. (Pubmed Central) -  Feb 18, 2021   
    There is substantial heterogeneity in reports of persistence and adherence rates with parenteral osteoporosis therapies. Most of the published data are from short-term studies and evaluations of long-term adherence and persistence with parenteral therapies for osteoporosis are needed.
  • ||||||||||  Review, Journal:  Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus. (Pubmed Central) -  Feb 17, 2021   
    We present the first systematic review characterising mAb-induced SCLE with respect to triggers, clinical signs, laboratory findings, prognosis and treatment approaches. We identify elevated rates associated with the use of checkpoint inhibitors and anti-TNFɑ agents.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    Review, Journal, Combination therapy:  Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives. (Pubmed Central) -  Feb 17, 2021   
    Combined teriparatide with denosumab appear to show the most substantial and clinically relevant skeletal benefits to osteoporotic patients. Additional research is necessary to define optimal methods of developing sequential and/or cyclical combinations of PTH and antiresorptive agents.
  • ||||||||||  Prolia (denosumab) / Amgen
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone (clinicaltrials.gov) -  Feb 15, 2021   
    P4,  N=70, Recruiting, 
    Additional research is necessary to define optimal methods of developing sequential and/or cyclical combinations of PTH and antiresorptive agents. Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Jan 2023 | Initiation date: Aug 2020 --> Feb 2021 | Trial primary completion date: Feb 2022 --> Jul 2022
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    [VIRTUAL] Diagnostic Challenges in Head and Neck and Endocrine Pathology - Stojanov () -  Feb 15, 2021 - Abstract #USCAP2021USCAP_609;    
    GCLJ may occur sporadically, syndromically, or in the setting of hyperparathyroidism. The majority of GCLJ are central giant cell granulomas (CGCG), benign neoplasms characterized in most cases by TRPV4 , KRAS , or FGFR1 mutations.
  • ||||||||||  Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
    [VIRTUAL] Clinicopathologic and Molecular Features of Denosumab-Treated Giant Cell Tumor of Bone: Analysis of 21 Cases () -  Feb 15, 2021 - Abstract #USCAP2021USCAP_480;    
    While the tumors can differ significantly from the conventional GCTB morphologically, they still exhibit similar histone H3 mutation profile. Clinical history of denosumab administration, radiographic findings, awareness of the histological features of DT-GCTB, and IHC and molecular studies for histone H3 mutations are important to avoid misdiagnosis.